Press coverage about Boston Scientific (NYSE:BSX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Boston Scientific earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 46.4750765632531 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Boston Scientific to Participate in 17th Annual Needham Healthcare Conference (finance.yahoo.com)
- Norinchukin Bank The Purchases 7662 Shares of Boston Scientific Co. (BSX) – Brinkwire (press release) (en.brinkwire.com)
- A Look at Analysts’ Recent Recommendations for Medtronic Stock (finance.yahoo.com)
- Boston Scientific Announces Scheduled Presentations at EHRA 2018 Congress (finance.yahoo.com)
- Medtronic Launches Its Resolute Onyx 2.0 mm DES (finance.yahoo.com)
Several equities analysts have issued reports on BSX shares. TheStreet raised shares of Boston Scientific from a “c+” rating to a “b” rating in a report on Thursday, January 18th. BMO Capital Markets reaffirmed a “buy” rating and set a $31.00 price objective on shares of Boston Scientific in a report on Wednesday, November 29th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Boston Scientific in a report on Wednesday, November 29th. Canaccord Genuity decreased their price objective on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, November 29th. Finally, SunTrust Banks set a $33.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a report on Monday, December 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Boston Scientific currently has an average rating of “Buy” and an average target price of $31.06.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.34. The firm had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.39 billion. Boston Scientific had a net margin of 1.15% and a return on equity of 24.27%. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period last year, the firm posted $0.30 earnings per share. analysts expect that Boston Scientific will post 1.37 earnings per share for the current year.
In other Boston Scientific news, SVP David A. Pierce sold 4,508 shares of Boston Scientific stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $27.54, for a total transaction of $124,150.32. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP John Bradley Sorenson sold 1,950 shares of Boston Scientific stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $27.43, for a total transaction of $53,488.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,276 shares of company stock worth $4,592,464. Insiders own 0.74% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/2018/03/14/boston-scientific-bsx-given-daily-news-impact-rating-of-0-17/2031066.html.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.